Susanne Flanders practices patent litigation with a focus on biotechnology, chemicals, pharmaceuticals, and medical devices. She has experience litigating patent infringement cases arising under the Hatch-Waxman Act and pertaining to drugs for treating various diseases including kidney disease, Alzheimer’s disease, tuberous sclerosis complex, and several types of cancer including colorectal cancer, pancreatic neuroendocrine tumors, breast cancer, and renal cell carcinoma. She has handled various aspects of litigations on behalf of pharmaceutical industry leaders including pre-suit investigations, fact and expert discovery, development of case strategy, legal and fact research, and motion practice. She has also been an integral member of several trial teams in federal district courts across the country and has contributed to appellate briefs before the Federal Circuit.
Susanne is additionally committed to Pro Bono assistance and has successfully represented clients in a variety of matters, including claims pertaining to unlawful discriminatory practices and unlawful retaliation under New York City and New York State Human Rights and Corrections Laws.
While in law school, Susanne served as the Executive Notes and Comments Editor of the Journal of Law and Policy.
Bone Care International, L.L.C. and Genzyme Corporation v. Roxane Laboratories, Inc., Sandoz, Inc., and Anchen Pharmaceuticals, Inc.,
(D. Del. June 12, 2012)
Susanne was part of the trial team that successfully defended [in a five-day bench trial] Genzyme’s patent relating to a vitamin-D analog used in the treatment of dialysis patients.